Clinical trials: Cutaneous Malignant Melanoma
Metastatic Melanoma, Recurrent Melanoma
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well aldesleukin with or without ziv-aflibercept works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7
- Trial name
- NCT01258855
- Testing
- Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept
- Where
- 21 sites in United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
RATIONALE: Biological therapies, such as hu14.18-interleukin-2 fusion protein, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00109863
- Testing
- hu14.18-IL2 fusion protein
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
Melanoma (Skin), Non-melanoma Skin Cancer
Nevus Doctor Clinical Decision Support for GPs
The study investigates if a computer-based clinical decision support tool for skin cancer may improve the diagnostic accuracy of general practitioners (GPs).
- Conditions
- Melanoma (Skin), Non-melanoma Skin Cancer, Actinic Keratoses
- Trial name
- NCT03246412
- Testing
- Nevus doctor clinical decision support
- Where
- Norway
- Volunteers
- 35 people
- Sponsor
- University Hospital of North Norway
Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
- Conditions
- Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer
- Trial name
- PACT (NCT02791334)
- Testing
- LY3300054, Ramucirumab, Abemaciclib
- Where
- 14 sites in United States, Belgium and 5 more
- Volunteers
- 164 people
- Sponsor
- Eli Lilly and Company
Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin
Skin Cancer Among Outdoor Workers
This observational study examines skin cancer among workers who may have prolonged occupational exposure to sunlight. Long-term exposure to ultraviolet radiation from the sun is an important risk factor for several types of skin…
- Conditions
- Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin, Squamous Cell Cancer of Head and Neck (SCCHN), Work Injury
- Trial name
- Skin Cancer Am (NCT07831083)
- Where
- Israel
- Volunteers
- 10,000 people
- Sponsor
- Assuta Medical Center
Kidney Cancer, Melanoma (Skin)
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00550654
- Testing
- questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Skin Cancer, Melanoma
Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component)
To determine the relationships of dietary factors with the subsequent risk of dermatological diseases (such as skin cancers and inflammatory or autoimmune dermatoses) in a cohort of female registered nurses and male health…
- Conditions
- Skin Cancer, Melanoma, Non-melanoma Skin Cancer, Psoriasis
- Trial name
- NCT03253666
- Testing
- Nutrient Intake
- Volunteers
- 173,229 people
- Sponsor
- Harvard School of Public Health (HSPH)
Melanoma (Skin)
Zr89 + PET Companion Trial
Study of Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT as an imaging biomarker for assessing an early response to therapy in patients with advanced melanoma on immunotherapy and hydroxychloroquine.
- Trial name
- NCT05279027
- Testing
- Zirconium Zr 89 Crefmirlimab Berdoxa
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Advanced Solid Tumor, Locally Advanced Solid Tumor
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC
- Trial name
- NCT04799054
- Testing
- TransCon TLR7/8 Agonist, Pembrolizumab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 188 people
- Sponsor
- Ascendis Pharma Oncology Division A/S
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
This phase I trial identifies the best dose of ipilimumab that can be administered through the DoseConnect™ device followed by nivolumab in treating patients with stage III melanoma that cannot be removed by surgery…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
- Trial name
- NCT04967196
- Testing
- Ipilimumab, Nivolumab, Lymph Node Assessment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Melanoma (Skin), Melanoma, Stage II, Stage I
Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma
A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app.
- Conditions
- Melanoma (Skin), Melanoma, Stage II, Stage I, Melanoma Stage, Survivorship
- Trial name
- Melanoma SCP (NCT06643286)
- Testing
- Digizorg Melanoma app
- Where
- 4 sites in Netherlands
- Volunteers
- 180 people
- Sponsor
- Erasmus Medical Center
Melanoma (Skin), Melanoma
Pembrolizumab and EDP1503 in Advanced Melanoma
This study is being done to determine if orally administered EDP1503 will enhance the response to standard immunotherapy treatment (pembrolizumab) in participants with advanced melanoma.
- Trial name
- NCT03595683
- Testing
- Pembrolizumab, EDP1503
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Chicago
Erysipelas, Impetigo
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
The purpose of this study is to demonstrate the validity and utility of a tele-dermatology system in the midterm periodic screening of non-widespread skin lesions of recent onset or for which a specialized early classification is…
- Conditions
- Erysipelas, Impetigo, Herpes Zoster, Molluscum Contagiosum
- Trial name
- NCT02902822
- Testing
- Screening, Tele-dermatology
- Where
- Italy
- Volunteers
- 461 people
- Sponsor
- Centro Studi Gised
Cutaneous Metastatic Melanoma
The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma
The investigators aim to include 100 local participants over the next 5 years in a two-stage sequential randomized interventional study of intralesional Interleukin-2 (IL-2) and Bacillus Calmette Guerin (BCG) to assess the…
- Trial name
- NCT03928275
- Testing
- Interleukin-2, Combination therapy Interleukin-2 and Bacillus Calmette Guerin
- Sponsor
- Carman Giacomantonio
Melanoma (Skin)
Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors
This project will pilot test whether a wearable device that tracks sun exposure and provides alerts regarding sun exposure and protection behaviors will reduce sunburns in melanoma survivors.
- Trial name
- NCT03518229
- Testing
- Microsoft Band 2 + UV messaging, Microsoft Band 2
- Sponsor
- University of Minnesota
Basal Cell Carcinoma, Squamous Cell Carcinoma Skin
Skin Cancer and Hyperthermia and Radiotherapy
The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).
- Conditions
- Basal Cell Carcinoma, Squamous Cell Carcinoma Skin, Non-melanoma Skin Cancer
- Trial name
- SAHARA (NCT06384053)
- Testing
- Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined, Radiotherapy (RT)
- Where
- 4 sites in Switzerland
- Volunteers
- 100 people
- Sponsor
- Kantonsspital Winterthur KSW
Breast Cancer, Colorectal Cancer
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma
- Trial name
- STARLING (NCT05576077)
- Testing
- TBio-4101, Pembrolizumab
- Where
- 13 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Turnstone Biologics, Corp.
Breast Cancer, Ovarian Cancer
Dermatological Effects and Quality of Life in Oncology Patients
This is a monocentric, low-risk interventional study designed to characterize established treatment-related dermatologic toxicity in patients receiving systemic anticancer therapies.
- Conditions
- Breast Cancer, Ovarian Cancer, NSCLC (Non-small Cell Lung Cancer), Melanoma (Skin Cancer)
- Trial name
- ReGenera (NCT07869186)
- Testing
- skin barrier assessment
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- European Institute of Oncology
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene